L’Oreal SA will have access to Micreos’ proprietary endolysin through a licensing deal announced on 29 October, underscoring the beauty firm’s growing focus on the skin microbiome and its role in skin health.
Laurent Attal, L’Oreal’s executive vice president, research and innovation, states, “For 15 years, L'Oréal's Research & Innovation has been cooperating with scientific institutions and conducting clinical studies to better understand the role of the skin microbiome
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?